EP 3573980 A4 20200819 - COMPOUNDS
Title (en)
COMPOUNDS
Title (de)
VERBINDUNGEN
Title (fr)
COMPOSÉS
Publication
Application
Priority
- CN 2017072587 W 20170125
- CN 2017072610 W 20170125
- CN 2017072612 W 20170125
- CN 2018073846 W 20180123
Abstract (en)
[origin: WO2018137619A1] The present invention provides novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
IPC 8 full level
C07D 413/14 (2006.01); A61K 31/5377 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01)
CPC (source: EP US)
A61P 25/16 (2017.12 - EP); A61P 25/28 (2017.12 - EP); C07D 413/14 (2013.01 - EP US)
Citation (search report)
- [A] WO 2014134774 A1 20140912 - MERCK SHARP & DOHME [US], et al
- [A] WO 2014134776 A1 20140912 - MERCK SHARP & DOHME [US], et al
- See references of WO 2018137619A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2018137619 A1 20180802; BR 112019015252 A2 20200414; CA 3050023 A1 20180802; CN 110248936 A 20190917; EP 3573980 A1 20191204; EP 3573980 A4 20200819; JP 2020505459 A 20200220; US 2019389850 A1 20191226
DOCDB simple family (application)
CN 2018073846 W 20180123; BR 112019015252 A 20180123; CA 3050023 A 20180123; CN 201880008483 A 20180123; EP 18744077 A 20180123; JP 2019560448 A 20180123; US 201816480937 A 20180123